Article in Planta medica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors at 3 institutions in 2 countries.
Jucélia Iantas *Postgraduate Program in Microbiology, Department of Pathology, Federal University of Paraná (UFPR), Curitiba, Brazil.
Daiani Cristina SaviPostgraduate Program in Genetics, Department of Genetics, Federal University of Paraná (UFPR), Curitiba, Brazil.
Larissa V PonomarevaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, United States.
Jon S ThorsonDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, United States.
Jürgen RohrDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, United States.
Chirlei GlienkePostgraduate Program in Microbiology, Department of Pathology, Federal University of Paraná (UFPR), Curitiba, Brazil.
Khaled A Shaaban *Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, United States.ORCID 0000-0001-7638-4942
University of Kentucky · USUniversidade Federal do Paraná · BRUniversidade Sociedade Educacional de Santa Catarina · BR
Funding
Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2M
Understanding the role of anti-apolipoprotein A-I antibodies in atherosclerotic cardiovascular diseaseP20GM130456 · NIGMS · UNIVERSITY OF KENTUCKY · PI Jon Scott Thorson · 2020 to 2026
$18.7M
Kentucky Center for Clinical and Translational ScienceUL1TR000117 · NCATS · UNIVERSITY OF KENTUCKY · PI KERN, PHILIP A · 2012 to 2015
$13.3M
In Vitro Glycorandomization of Natural ProductsR37AI052218 · NIAID · UNIVERSITY OF KENTUCKY · PI THORSON, JON SCOTT · 2012 to 2021
$4.0M
Mechanistic and pharmacologic studies of selective mithramycin analogues targeting EWS-FLI1 in Ewing sarcomaR01CA243529 · NCI · UNIVERSITY OF KENTUCKY · PI LEGGAS, MARKOS, ROHR, JURGEN T · 2020 to 2024
$3.0M
Platform technologies for understanding and exploiting methylationR01GM115261 · NIGMS · UNIVERSITY OF KENTUCKY · PI PHILLIPS, GEORGE NEAL, THORSON, JON SCOTT · 2016 to 2019
$2.2M
Bruker AVANCE NEO 600 MHz High-Performance Digital NMR SpectrometerS10OD028690 · OD · UNIVERSITY OF KENTUCKY · PI GARNEAU-TSODIKOVA, SYLVIE · 2020 to 2020
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Paecilins Q and R: Antifungal Chromanones Produced by the Endophytic Fungus Pseudofusicoccum stromaticum CMRP4328. · full record | OpenQuestion